CIMETIDINE 600 MG
CIMETIDINE : 600 MG · DIN 00600067 · AA PHARMA INC
Health Canada status: DORMANT
What is CIMETIDINE?
CIMETIDINE 600 MG contains CIMETIDINE : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 00600067, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 22-Jan-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CIMETIDINE used for?
Duodenal and non-malignant gastric ulcer; prophylaxis of recurrent ulcers; GERD; pathological hypersecretion (Zollinger-Ellison); NSAID-induced lesions; adjunctive therapy in cystic fibrosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00600067 |
|---|---|
| Brand name | CIMETIDINE |
| Generic / active ingredient | CIMETIDINE : 600 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 600 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BA01 CIMETIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 22-Jan-2019 |
| Original market date | 1983-12-31 00:00:00 |
How is it administered?
Adults: 800-1200 mg/day for ulcers; 1.2 g/day for GERD; up to 2400 mg/day for hypersecretory conditions. Administered once daily at bedtime, twice daily, or four times daily with meals and at bedtime.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Information not explicitly provided in the provided text sections (Section 11 is listed in TOC but content is missing).
How is it supplied?
Bottles of 100, 500, and 1000 tablets (depending on strength).
Contraindications
Hypersensitivity to the drug or to any ingredient in the formulation.
Warnings and precautions
Symptomatic response does not preclude gastric malignancy; treatment can mask symptoms of gastric cancer. Use caution in elderly due to risk of confusional states.
Is CIMETIDINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AA PHARMA INC, last seen 16 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A02BA01 CIMETIDINE. 2 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CIMETIDINE | 200 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00584215 |
| CIMETIDINE | 300 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00487872 |
| APO-CIMETIDINE ORAL SOLUTION | 300 MG / 5 ML | LIQUID | APOTEX INC | CANCELLED POST MARKET | DIN 02243085 |
| CIMETIDINE | 400 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00600059 |
| CIMETIDINE | 800 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00749494 |
| CIMETIDINE 200 TAB 200MG | 200 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00596469 |
| CIMETIDINE TAB 300MG | 300 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00596477 |
| CIMETIDINE TAB 400MG | 400 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00618691 |
| CIMETIDINE TAB 600MG | 600 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00618705 |
| DOM-CIMETIDINE | 200 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231285 |
Who else supplies CIMETIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CIMETIDINE appears in 47 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.